| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Novartis AG | SB17 ustekinumab - (biosimilar) | Autoimmune disorders including Crohn's disease, plaque psoriasis, psoriatic arthritis, and ulcerative colitis | Phase 3 | Subcutaneous | Immunology: Anti-TNF | |
| Novartis AG | Leqvio (ORION-8) | Atherosclerotic cardiovascular disease (ASCVD), increased risk of ASCVD or heterozygous familial hypercholesterolemia (HeFH) | Phase 3 | Data Released | Subcutaneous | Cardiology |
| Novartis AG | Kesimpta (ofatumumab) - (ALITHIOS) | Relapsing Multiple Sclerosis | Phase 3 | Data Released | Subcutaneous | Neurology |
| Novartis AG | Iptacopan - (APPOINT-PNH) | Paroxysmal nocturnal hemoglobinuria (PNH) | Phase 3 | Data Released | Oral | Hematology |
| Novartis AG | Coartem (artemether-lumefantrine) - (CALINA) | Malaria in babies <5 kg | Phase 2/3 | Data Released | Oral | Antimalarial |
| Novartis AG | CNP520 | Alzheimer’s Disease | Phase 2/3 | Trial Discontinued | oral | Neurology |
| Novartis AG | TOUR006 - (spiriTED) | Thyroid Eye Disease (TED) | Phase 2b | Ongoing | Intravenous | Opthalmic |
| Novartis AG | XXB750 | Hypertension | Phase 2b | Trial Discontinued | Intravenous | Cardiology |